District Court Narrowly Defines the Relevant Market in Post-Actavis Pay-For-Delay Suit

by Patterson Belknap Webb & Tyler LLP

On August 8, the District of Connecticut issued a noteworthy ruling on how to approach defining the relevant market definition in a pay-for-delay suit.  In In re Aggrenox Antitrust Litigation, 3:14-md-02516 (D. Conn.), three groups of purchasers allege that Boehringer Ingelheim unlawfully paid Barr Pharmaceuticals (a business unit of generic manufacturer, Teva) to delay entry of a generic of the blood-clot medication Aggrenox.  The district court held that the relevant market in pay-for-delay litigation is “determined by the nature of the challenged agreement,” and thus concluded that the only relevant market at issue in this suit is the market for Aggrenox and its generic equivalent and did not include drugs that therapeutically competed against Aggrenox.

The ruling comes in an unusual context: after defendants sought discovery regarding competing drugs, the Court issued an order for the defendants to show cause why the Court should not restrict the evidence in this case to solely the market for Aggrenox and its bioequivalent.  Concluding that the market should be defined that narrowly, the district court refused to permit discovery into, or evidence relating to, other drugs that therapeutically compete against Aggrenox, concluding that such discovery and evidence would be “irrelevant.”

The district court recognized Aggrenox as an “important case in the relatively new landscape of Actavis actions.”  Op. at p. 12.  And indeed this ruling may provide some indication how trial courts will approach the issue of defining the relevant market—and consequently the brand company’s market power—in pay-for-delay litigation following the Supreme Court’s ruling in FTC v. Actavis, Inc., 133 S. Ct. 2223 (2013).

We have extensively covered Actavis and its progeny in previous posts.  In Actavis, the Supreme Court held that reverse payment settlements—in which name-brand drug manufacturers pay generic rivals to keep cheaper alternatives off the market—can “sometimes violate the antitrust laws” because their “anticompetitive consequences [can] at least sometimes prove unjustified.”  In reaching this conclusion, the Supreme Court rejected several possible analyses (e.g., a rule of presumptive illegality and “scope of the patent” test) in favor of a traditional antitrust “rule of reason” analysis.  But as we discussed here, the Actavis court did not flesh out the contours of this analysis, instead leaving the task to the lower courts to develop the antitrust jurisprudence of reverse payments.  Thus the Aggrenox decision comes in the midst of an uncertain period, in which lower courts are grappling with how to interpret Actavis’s directives and attempt to reconcile the competing policies of antitrust and patent law.

In issuing the Aggrenox ruling, the district court explained that it was seeking to “provide some of the missing structure” to the antitrust analysis that Actavis left unanswered.  The district court noted that Actavis identified several factors that should be considered in determining whether a reverse payment settlement is likely to produce anticompetitive effect, including the payment’s “size, its scale in relation to the payor’s anticipated future litigation costs, its independence from other services for which it might represent payment, and the lack of any other convincing justification.”  Actavis, 133 S. Ct. at 2237.  Although Actavis did not expressly include determining the brand’s market power in that list of factors, the district court noted, that decision “allude[d] to the concept” of market power in laying out these factors, since “patents are only valuable as a result of whatever market power they confer” and thus “the size and circumstances of the reverse payment are suggestive of the market power conferred by the patent.”  Op. at pp. 3-4.

The district court opined that, “as a practical matter, the only ‘relevant’ market in this case, and in similar cases brought under FTC v. Actavis, will be the market in which the challenged settlement agreement allegedly acted as an anticompetitive constraint:  that is, in this case, it will be implicitly defined by the scope of the disputed patent.”  Op. at p. 5.  As a result, drugs that may therapeutically compete against the drug at issue are necessarily outside the scope of the relevant market.  Additionally, the court held, to the extent these drugs actually competed with Aggrenox, any substitution effect constraining the price for Aggrenox will already be “priced in” to this analysis, thus making sales and pricing data about other drugs “redundant.”  Op. at p. 8.

Although the district court noted that the existence of the patent would not necessarily indicate that defendants possessed market power, it would be “vanishingly unlikely” that a large reverse payment would be made where the defendants did not possess market power which it sought to protect by such a payment.  Id.  Accordingly, the district court held, a large reverse payment should be considered a “strong indicator of market power.”  Id.  While the district court carefully noted that a large reverse payment is not dispositive of antitrust liability, it also indicated that “reverse payments beg to be explained.”  Op. at p. 4.

In recognition of the ongoing uncertainty among the lower courts as to the appropriate way to implement Actavis, in the same order the district court exercised its discretion under 28 U.S.C. § 1292(b) to certify the issue for interlocutory appeal.  It is not yet clear whether the Second Circuit will accept the interlocutory appeal.  We will continue to monitor this and other pay-for-delay litigation to see how this rule-of-reason analysis continues to develop in the wake of Actavis.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Patterson Belknap Webb & Tyler LLP | Attorney Advertising

Written by:

Patterson Belknap Webb & Tyler LLP

Patterson Belknap Webb & Tyler LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.